Shalabh Gupta
Chief Executive Officer chez UNICYCIVE THERAPEUTICS, INC.
Fortune : 8 M $ au 31/03/2024
Profil
Shalabh Gupta is the founder of Globavir Biosciences, Inc. (founded in 2013) where he holds the title of Chief Executive Officer.
He is also the founder of Unicycive Therapeutics, Inc. (founded in 2016) where he holds the titles of Chairman, President & Chief Executive Officer.
Additionally, he founded Biocycive, Inc. in 2010 and served as the Chief Executive Officer.
Currently, Dr. Gupta is the Director at Beall Center For Innovation & Entrepreneurship since 2018.
He is also the Director-Wagner Alumni Association at Wagner College (New York).
Furthermore, he has been a Member of The Indus Entrepreneurs since 2013.
In the past, Dr. Gupta worked as the Medical Director at Synageva BioPharma Corp.
He also served as a Director at Phenomenome Discoveries, Inc. Additionally, from 2009 to 2010, he was the Head-Commercial Strategy at Genentech, Inc.Dr. Gupta holds a doctorate degree from Jawaharlal Institute of Post Graduate Medical Education & Re.
He also has a graduate degree from NYU Wagner.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
UNICYCIVE THERAPEUTICS, INC.
16,89% | 15/04/2024 | 5 871 726 ( 16,89% ) | 8 M $ | 31/03/2024 |
Postes actifs de Shalabh Gupta
| Sociétés | Poste | Début |
|---|---|---|
| UNICYCIVE THERAPEUTICS, INC. | Chief Executive Officer | 18/08/2016 |
Globavir Biosciences, Inc.
 Globavir Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Globavir Biosciences, Inc. develops therapeutics and diagnostics for the treatment of infectious diseases. The American company was founded in 2011 by Shalabh Gupta, who has been the CEO since 2011. | Chief Executive Officer | 01/06/2013 |
| Beall Center For Innovation & Entrepreneurship | Director/Board Member | 01/01/2018 |
The Indus Entrepreneurs
 The Indus Entrepreneurs Miscellaneous Commercial ServicesCommercial Services The Indus Entrepreneurs is a non-profit organization. It provides mentoring, networking, education and funding to entrepreneurs. The company was founded in 1992 and is headquartered in Santa Clara, CA. | Corporate Officer/Principal | 01/01/2013 |
| Wagner College (New York) | Corporate Officer/Principal | - |
Anciens postes connus de Shalabh Gupta
| Sociétés | Poste | Fin |
|---|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/09/2010 |
Synageva BioPharma Corp. /Old/
 Synageva BioPharma Corp. /Old/ BiotechnologyHealth Technology Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™. | Corporate Officer/Principal | - |
Phenomenome Discoveries, Inc.
 Phenomenome Discoveries, Inc. Miscellaneous Commercial ServicesCommercial Services Phenomenome Discoveries, Inc. provides human health research tools to discover metabolite biomarkers. Its services include discovery, analytics, informatics, collaborators and analytical services. The company was founded by John Hyshka and Dayan B. Goodenowe in 2000 and is headquartered in Saskatoon, Canada. | Director/Board Member | - |
Biocycive, Inc.
 Biocycive, Inc. BiotechnologyHealth Technology Part of Sorrento Therapeutics, Inc., Biocycive, Inc. is a biotechnology company focused on oncology. The private company is based in Los Altos, CA. The company was founded in 2010 by Shalabh Gupta. Biocycive was acquired by Sorrento Therapeutics, Inc. on January 31, 2015 for $160 million. | Chief Executive Officer | - |
Formation de Shalabh Gupta
| Jawaharlal Institute of Post Graduate Medical Education & Re | Doctorate Degree |
| NYU Wagner | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Synageva BioPharma Corp. /Old/
Synageva BioPharma Corp. /Old/ BiotechnologyHealth Technology Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™. | Health Technology |
The Indus Entrepreneurs
The Indus Entrepreneurs Miscellaneous Commercial ServicesCommercial Services The Indus Entrepreneurs is a non-profit organization. It provides mentoring, networking, education and funding to entrepreneurs. The company was founded in 1992 and is headquartered in Santa Clara, CA. | Commercial Services |
Phenomenome Discoveries, Inc.
Phenomenome Discoveries, Inc. Miscellaneous Commercial ServicesCommercial Services Phenomenome Discoveries, Inc. provides human health research tools to discover metabolite biomarkers. Its services include discovery, analytics, informatics, collaborators and analytical services. The company was founded by John Hyshka and Dayan B. Goodenowe in 2000 and is headquartered in Saskatoon, Canada. | Commercial Services |
Globavir Biosciences, Inc.
Globavir Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Globavir Biosciences, Inc. develops therapeutics and diagnostics for the treatment of infectious diseases. The American company was founded in 2011 by Shalabh Gupta, who has been the CEO since 2011. | Commercial Services |
| Unicycive Therapeutics, Inc. | |
Biocycive, Inc.
Biocycive, Inc. BiotechnologyHealth Technology Part of Sorrento Therapeutics, Inc., Biocycive, Inc. is a biotechnology company focused on oncology. The private company is based in Los Altos, CA. The company was founded in 2010 by Shalabh Gupta. Biocycive was acquired by Sorrento Therapeutics, Inc. on January 31, 2015 for $160 million. | Health Technology |
| Beall Center For Innovation & Entrepreneurship |
